SAN DIEGO, Nov. 3, 2010 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR), a real estate investment trust focused on Providing Real Estate to the Life Science Industry®, today announced financial results for the third quarter ended September 30, 2010.
Third Quarter 2010 Highlights
Subsequent to quarter end, the company completed the closings of its previously announced acquisitions of 489,000 square feet of laboratory and office properties in South San Francisco and 195,000 square feet of laboratory and office properties in the Sorrento Valley submarket of San Diego. With these acquisitions, the company's total portfolio now comprises 82 properties and 12.1 million square feet and an additional 2.6 million square feet of development potential.
In addition, subsequent to quarter end, the company executed two leases for a total of 65,000 square feet at the Pacific Research Center in Newark, California.
"Team BioMed delivered another outstanding quarter which produced record rental and total revenues built on the strength of our sustained leasing success and our recent acquisitions," said Alan D. Gold, Chairman and Chief Executive Officer of BioMed. "We continued to execute on our proven business strategy of investing in high-quality research facilities, well-located within the core life science markets. Our investment successes in the third quarter and into the fourth quarter have enabled us to expand our footprint in the South San Francisco and San Diego markets by almost one million square feet with preeminent life science tenants such as Elan Pharmaceuticals, Genentech, Amylin Pharmaceuticals, Bristol-Myers Squibb, Halozyme Therapeutics and the University of California, San Diego. We are very excited about these additions to our world-class portfolio and look forward to supporting the important research and commercialization efforts of our newest tenant partners."
Third Quarter Financial ResultsRental revenues for the third quarter were $73.0 million, compared to $68.5 million for the same period in 2009, an increase of 6.6% and, for the second consecutive quarter, the highest in the company's history. Total revenues for the third quarter were $95.7 million, compared to $93.0 million for the same period in 2009, an increase of 3.0% and the highest in the company's history.
The current operating portfolio's weighted average leased percentage was 88.2% as of September 30, 2010 and the same property portfolio increased to 88.2% leased as of September 30, 2010, up 190 basis points from the same period in 2009. Same property net operating income on a cash basis increased 6.1% for the quarter compared to the same period in 2009, primarily as a result of contractual rent escalations and increased occupancy.
Net income available to common stockholders for the third quarter was $4.8 million, or $0.04 per diluted share, compared to $4.1 million, or $0.04 per diluted share, for the same period in 2009. FFO for the quarter was $35.2 million, or $0.28 per diluted share, compared to $35.8 million, or $0.35 per diluted share, for the same period in 2009.
FFO is a supplemental non-GAAP financial measure used in the real estate industry to measure and compare the operating performance of real estate companies. A complete reconciliation containing adjustments from GAAP net income available to common stockholders to FFO and a definition of FFO are included at the end of this release.
Portfolio UpdateThe company executed 14 leasing transactions during the quarter representing approximately 231,700 square feet, comprised of:
During the quarter ended September 30, 2010, the company completed the following acquisitions:
As of September 30, 2010, BioMed owned or had interests in 125 buildings, located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey. As of September 30, 2010, the company had 136 tenants.
The company's property portfolio included the following as of September 30, 2010:Rentable Square FeetCurrent operating9,660,606Long-term lease up1,389,517Development176,000Pre-development152,145Total property portfolio11,378,268Development potential1,680,000Total portfolio13,058,268After quarter end, the company acquired the following properties:
Financing ActivityAt September 30, 2010, the company's debt to total assets ratio was 31.4%, the lowest since March 31, 2005. During the third quarter, the company completed the following financing transactions:
According to Kent Griffin, BioMed's President, "Throughout our history, and particularly over the last two years, we have taken a series of steady, measured steps to effectively manage our capital structure. This discipline has proven particularly beneficial in 2010 as we have been able to leverage our competitive advantages to execute on attractive investment opportunities that we believe will be very beneficial to our shareholders. Equally important, our investment activity, which has included more than 1.5 million square feet year-to-date, has been focused on high quality, well located laboratory and office space that further enhances our leading market position."
Quarterly and Annual DistributionsBioMed's board of directors previously declared a third quarter 2010 dividend of $0.17 per share of common stock, and a dividend of $0.46094 per share of the company's 7.375% Series A Cumulative Redeemable Preferred Stock for the period from July 16, 2010 through October 15, 2010. The third quarter common share dividend represented a 13.3% increase over the second quarter 2010 dividend, and a 54.5% increase over the third quarter 2009 dividend, and is equivalent to an annualized dividend of $0.68 per common share.
Earnings GuidanceThe company is reporting its fourth quarter 2010 guidance for net income per diluted share and FFO per diluted share to reflect the impact of the recent acquisitions and capital activity. The company's guidance is set forth and reconciled below. Projected FFO per diluted share is based upon estimated, weighted-average diluted common shares outstanding of approximately 144 million for the fourth quarter.Three months endedDecember 31, 2010(Low - High)Projected net income per diluted share availableto common stockholders
$0.07 – $0.08 Add:Noncontrolling interests in operating partnership
$0.00Real estate depreciation and amortization
$0.21 Less:Assumed conversion of senior exchangeable notes due 2030
($0.01)Projected FFO per diluted share
$0.27 – $.0.28The company's fourth quarter 2010 guidance does not include any assumptions related to future financing or investing activities beyond announced transactions, but does include the impact of the assumed conversion of the company's exchangeable senior notes due 2030.
The company's initial 2011 guidance for net income per diluted share and FFO per diluted share is set forth and reconciled below. Projected FFO per diluted share is based upon estimated, weighted-average diluted common shares outstanding of approximately 144 million for the full year, including the impact of the assumed conversion of the company's exchangeable senior notes due 2030.2011(Low - High)Projected net income per diluted share availableto common stockholders
$0.35– $0.45 Add:Noncontrolling interests in operating partnership
$0.01Real estate depreciation and amortization
$0.83 Less:Assumed conversion of senior exchangeable notes due 2030
($0.04)Projected FFO per diluted share
$1.15 – $1.25At the mid-point, the company's 2011 FFO guidance represents a 7.1% increase over the annualized results for the third quarter of 2010.
The 2011 guidance includes the following assumptions:
The foregoing estimates are forward-looking and reflect management's view of current and future market conditions, including certain assumptions with respect to leasing activity, rental rates, occupancy levels, interest rates, and the amount and timing of acquisitions and development and redevelopment activities. The company's actual results may differ materially from these estimates.
Supplemental InformationSupplemental operating and financial data, as well as the updated Investor Presentation, are available in the Investor Relations section of the company's website at www.biomedrealty.com.
Teleconference and Webcast BioMed will conduct a conference call and webcast at 9:00 a.m. Pacific Time (12:00 noon Eastern Time) on Thursday, November 4, 2010 to discuss the company's financial results and operations for the quarter. The call will be open to all interested investors either through a live audio web cast at the Investor Relations section of the company's web site at www.biomedrealty.com and at www.earnings.com, which will include an online slide presentation to accompany the call, or live by calling 800-599-9795 (domestic) or 617-786-2905 (international) with call ID number 17348989. The complete webcast will be archived for 30 days on both web sites. A telephone playback of the conference call will also be available from 1:00 p.m. Pacific Time on Thursday, November 4, 2010 until midnight Pacific Time on Tuesday, November 9, 2010 by calling 888-286-8010 (domestic) or 617-801-6888 (international) and using access code 40125473.
About BioMed Realty TrustBioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 82 properties, representing 144 buildings with approximately 12.1 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
(Financial Tables Follow)
BIOMED REALTY TRUST, INC.CONSOLIDATED BALANCE SHEETS(In thousands, except share data)September 30,2010December 31,2009(Unaudited)ASSETSInvestments in real estate, net$ 3,207,957
$ 2,971,767Investments in unconsolidated partnerships58,565
56,909Cash and cash equivalents20,687
15,355Accounts receivable, net7,333
4,135Accrued straight-line rents, net102,567
82,066Acquired above-market leases, net3,796
3,047Deferred leasing costs, net88,828
83,274Deferred loan costs, net12,394
38,676Total assets$ 3,572,553
$ 3,283,274LIABILITIES AND EQUITYMortgage notes payable, net$ 662,522
$ 669,454Secured term loan—
250,000Exchangeable senior notes due 2026, net19,432
44,685Exchangeable senior notes due 203180,000
—Unsecured senior notes due 2020, net247,523
—Unsecured line of credit14,050
7,929Dividends and distributions payable26,992
18,531Accounts payable, accrued expenses, and other liabilities75,319
12,551Acquired below-market leases, net8,031
1,459,342Equity:Stockholders' equity:Preferred stock, $.01 par value, 15,000,000 shares authorized: 7.375% Series A cumulative redeemable preferred stock, $230,000,000 liquidation preference ($25.00 per share), 9,200,000 shares issued and outstanding at September 30, 2010 and December 31, 2009
222,413 Common stock, $.01 par value, 200,000,000 and 150,000,000 shares authorized and 130,831,009 and 99,000,269 shares issued and outstanding at September 30, 2010 and December 31, 2009, respectively
990Additional paid-in capital2,369,952
1,843,551Accumulated other comprehensive loss(73,840)
(85,183)Dividends in excess of earnings(207,419)
(167,429)Total stockholders' equity2,312,414
1,823,932Total liabilities and equity$ 3,572,553
$ 3,283,274BIOMED REALTY TRUST, INC.CONSOLIDATED STATEMENTS OF INCOME(In thousands, except share data)(Unaudited)For the Three Months EndedSeptember 30,For the Nine Months EndedSeptember 30,2010200920102009Revenues:Rental$ 72,971
$ 202,608Tenant recoveries22,723
55,539Real estate taxes9,408
23,079Depreciation and amortization27,774
82,767General and administrative6,805
16,119Acquisition related expenses
177,748Income from operations31,328
95,246Equity in net loss of unconsolidated partnerships(308)
(44,567)(Loss)/gain on derivative instruments(287)
289(Loss)/gain on extinguishment of debt(22)
55,462Net income attributable to noncontrolling interests(104)
(1,458)Net income attributable to Company9,073
54,004Preferred stock dividends(4,241)
(12,722)Net income available to common stockholders$ 4,832
$ 41,282Net income per share available to common stockholders:
Basic and diluted earnings per share$ 0.04
$ 0.46Weighted-average common shares outstanding:
92,863,088BIOMED REALTY TRUST, INC.CONSOLIDATED FUNDS FROM OPERATIONS(In thousands, except share data)(Unaudited)Our FFO available to common shares and partnership and LTIP units and a reconciliation to net income for the three and nine months ended September 30, 2010 and 2009 was as follows:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2010200920102009Net income available to common stockholders
$ 41,282Adjustments:Noncontrolling interests in operating partnership
1,502Interest expense on exchangeable senior notes due 2030 (1)
-Depreciation and amortization — unconsolidated partnerships
1,986Depreciation and amortization — consolidated entities
82,767Depreciation and amortization — allocable to noncontrolling interest of consolidated joint ventures
(58)Funds from operations available to common shares and Units
$ 127,479Funds from operations per share — diluted
$ 1.37Weighted-average common shares and Units outstanding — diluted (2)
92,863,088(1) Reflects interest expense adjustment of the exchangeable senior notes due 2030 based on the "if converted" method. See Item 8.01 of the Form 8-K filed by the Company with the Securities Exchange Commission on September 22, 2010 for more information.(2) The three and nine months ended September 30, 2010 each include 9,914,076 shares of common stock potentially issuable pursuant to the exchange feature of the exchangeable senior notes due 2030 based on the "if converted" method, and 1,227,939 and 1,249,032 shares of unvested restricted stock, respectively, which are considered anti-dilutive for purposes of calculating diluted earnings per share.We present funds from operations, or FFO, available to common shares and partnership and LTIP units because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. FFO is intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO excludes depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, it provides a performance measure that, when compared year over year, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT, in its March 1995 White Paper (as amended in November 1999 and April 2002). As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures. Our computation may differ from the methodology for calculating FFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO does not represent amounts available for management's discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO should not be considered as an alternative to net income (loss) (computed in accordance with GAAP) as an indicator of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to pay dividends or make distributions.
|SOURCE BioMed Realty Trust, Inc.|
Copyright©2010 PR Newswire.
All rights reserved